Download PDF

1. Company Snapshot

1.a. Company Description

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally.The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia.It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.


The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd.in China, and Knight Therapeutics, Inc.in Canada for the development and commercialization of tenapanor in their respective territories.


The company was formerly known as Nteryx, Inc.and changed its name to Ardelyx, Inc.in June 2008.


Ardelyx, Inc.was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Show Full description

1.b. Last Insights on ARDX

Ardelyx's recent performance was negatively impacted by rising costs, including increased SG&A expenses and looming debt obligations. The company's limited pipeline and uncertain growth prospects, particularly with Xphozah's reimbursement issues and modest growth from Ibsrela, also contributed to the challenges. Additionally, the loss of Medicare Part D coverage for Xphozah limits revenue potential, despite the company's $750 million annual sales guidance.

1.c. Company Highlights

2. Ardelyx's Q4 and Full-Year 2025 Earnings: A Year of Strong Growth

Ardelyx reported a robust financial performance for 2025, with IBSRELA revenue growing 73% compared to 2024, driven by a strong demand quarter in Q4, which saw 61% year-over-year growth. The company's total revenue for IBSRELA is on track to reach $1 billion by 2029, as guided by management in January. The actual EPS came out at -$0.00167, missing estimates of $0.02. XPHOZAH also saw a 9% increase in total dispenses and a 41% increase in paid dispenses (excluding Medicare) in 2025.

Publication Date: Mar -07

📋 Highlights
  • IBSRELA Revenue Growth:: Achieved 73% annual growth (2024–2025) and 61% Q4 YoY growth, with $410–430M 2026 guidance and $1B revenue target by 2029.
  • CIC Label Expansion:: Launched Phase III trial for IBSRELA in chronic idiopathic constipation (CIC), targeting 18–20% efficacy vs. placebo (700-patient sample).
  • XPHOZAH Performance:: 9% total dispense growth (2025) and 41% paid dispense growth (excluding Medicare), with $110–120M 2026 revenue projection.
  • Financial Strength & Investment:: $265M cash reserves, 25% R&D expense increase in 2026 for pipeline (e.g., RDX-10531) and commercial infrastructure.
  • Market Positioning:: IBSRELA targets $1B peak revenue (2029) by capturing GCC agonist market (50K new IBS-C patients/month) and CIC expansion.

Revenue Growth Drivers

The growth in IBSRELA revenue was driven by a combination of factors, including a strong prescriber base, improved prescription pull-through, and patient engagement. Eric Foster, CFO, highlighted that the company is investing in three key areas to drive significant demand: the prescriber, prescription pull-through, and patient engagement. The company's guidance for 2026 revenues is between $410 million and $430 million, driven by quarter-over-quarter increases in demand and improved prescription pull-through.

Pipeline Progress

Ardelyx is making significant progress in its pipeline, with a Phase III trial for tenapanor, a treatment for CIC, and a Phase I trial for RDX-10531, a potential treatment for multiple therapeutic areas. Laura Williams, Chief Medical Officer, emphasized the need for a different mechanism of action in IBS-C and CIC, where tenapanor is expected to provide a good option for patients who are not getting relief from other treatments.

Valuation Metrics

Ardelyx's current valuation metrics indicate a P/S Ratio of 3.73, which suggests that the market is pricing in significant growth expectations. The EV/EBITDA ratio is -56.96, indicating that the company's enterprise value is not yet supported by its EBITDA. Analysts estimate next year's revenue growth at 34.2%, which may be challenging to achieve given the company's current financial performance. With a ROE of -40.63% and ROIC of -9.86%, the company's return on equity and invested capital is negative, indicating that it is not generating profits from its operations.

Outlook

Ardelyx's management expressed significant confidence in reaching the targeted revenue of $1 billion in IBSRELA revenues by 2029, driven by a large patient population and a growing market. The company plans to optimize its sales force, improve prescription pull-through, and increase its field reimbursement manager team to drive growth. As Michael Raab, CEO, stated, "We're looking at the data to determine the best dose for CIC, with the middle dose of 25 milligrams BID being a good starting point." This suggests that the company is committed to making data-driven decisions to drive its growth aspirations.

3. NewsRoom

Card image cap

Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

Mar -12

Source: globenewswire.com

Card image cap

Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

Mar -09

Source: globenewswire.com

Card image cap

Ardelyx to Participate in Upcoming Investor Conferences

Mar -04

Source: globenewswire.com

Card image cap

Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership

Mar -01

Source: fool.com

Card image cap

Michael Raab Sells 45,982 Shares of Ardelyx (NASDAQ:ARDX) Stock

Feb -25

Source: defenseworld.net

Card image cap

Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

Feb -24

Source: globenewswire.com

Card image cap

Ardelyx (NASDAQ:ARDX) Director David Mott Buys 333,333 Shares of Stock

Feb -24

Source: defenseworld.net

Card image cap

Why Ardelyx's Offensive Strategy Doesn't Move The Needle

Feb -21

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.97%)

6. Segments

Biopharmaceutical Products

Expected Growth: 8.97%

Ardelyx's biopharmaceutical products are driven by increasing demand for novel treatments, growing prevalence of chronic kidney disease and cardiorenal diseases, and the company's strong pipeline of innovative products, including tenapanor and RDX013. Additionally, strategic partnerships and collaborations are fueling growth, with a focus on expanding into new markets and indications.

7. Detailed Products

Tenapanor

Tenapanor is a minimally absorbed, oral, gut-restricted inhibitor of the sodium/hydrogen exchanger 3 (NHE3), in development for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic kidney disease (CKD).

RDX7675

RDX7675 is a novel, oral, non-absorbed phosphate binder in development for the treatment of hyperphosphatemia in patients with CKD on dialysis.

8. Ardelyx, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Ardelyx, Inc. has a moderate threat of substitutes due to the availability of alternative treatments for kidney disease and cardiovascular disease.

Bargaining Power Of Customers

Ardelyx, Inc. has a low bargaining power of customers due to the specialized nature of its products and the lack of alternative options for patients.

Bargaining Power Of Suppliers

Ardelyx, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and manufacturing services.

Threat Of New Entrants

Ardelyx, Inc. has a high threat of new entrants due to the growing demand for kidney disease and cardiovascular disease treatments and the availability of funding for biotech startups.

Intensity Of Rivalry

Ardelyx, Inc. operates in a highly competitive industry with several established players, leading to a high intensity of rivalry.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 25.13%
Debt Cost 8.26%
Equity Weight 74.87%
Equity Cost 8.26%
WACC 8.26%
Leverage 33.56%

11. Quality Control: Ardelyx, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Puma Biotechnology

A-Score: 5.4/10

Value: 7.3

Growth: 6.0

Quality: 8.6

Yield: 0.0

Momentum: 9.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
iTeos Therapeutics

A-Score: 4.9/10

Value: 7.8

Growth: 3.6

Quality: 4.4

Yield: 0.0

Momentum: 8.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Ardelyx

A-Score: 4.4/10

Value: 6.8

Growth: 6.1

Quality: 4.7

Yield: 0.0

Momentum: 7.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Ligand Pharmaceuticals

A-Score: 4.4/10

Value: 0.4

Growth: 4.4

Quality: 5.4

Yield: 0.0

Momentum: 10.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
Amylyx Pharmaceuticals

A-Score: 4.3/10

Value: 8.7

Growth: 3.6

Quality: 6.8

Yield: 0.0

Momentum: 5.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Applied Therapeutics

A-Score: 3.1/10

Value: 8.0

Growth: 6.9

Quality: 3.5

Yield: 0.0

Momentum: 0.5

Volatility: 0.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

5.31$

Current Price

5.31$

Potential

-0.00%

Expected Cash-Flows